We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $931M
1-Year Est. Return 41.63%
This Fund
S&P 500
This Quarter Est. Return
+31.31%
1 Year Est. Return
+41.63%
3 Year Est. Return
+181.18%
5 Year Est. Return
+113.34%
10 Year Est. Return
+1,823.73%
AUM
$2.59B
AUM Growth
+$94.3M
Cap. Flow
-$53.2M
Cap. Flow %
-2.05%
Top 10 Hldgs %
60.43%
Holding
115
New
13
Increased
19
Reduced
20
Closed
19

Top Buys

Rank Stock Value
1
BNTX icon
BioNTech
BNTX
+$58.9M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$29.9M
3
PYPL icon
PayPal
PYPL
+$20.8M
4
ARGX icon
argenx
ARGX
+$20.3M
5
HARP
Harpoon Therapeutics, Inc. Common Stock
HARP
+$12.9M

Top Sells

Rank Stock Value
1
MDCO
Medicines Co
MDCO
+$70M
2
NVDA icon
NVIDIA
NVDA
+$34.8M
3
AVTR icon
Avantor
AVTR
+$19.9M
4
GBT
Global Blood Therapeutics, Inc.
GBT
+$17M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$15.6M

Sector Composition

Rank Sector Weight
1 Healthcare 63.41%
2 Consumer Discretionary 25.71%
3 Miscellaneous 7.39%
4 Communication Services 1.46%
5 Technology 1.19%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BMY icon
101
CALL
Bristol-Myers Squibb
BMY
$130B
– –
-3,500,000
Closed -$177M
FIS icon
102
Fidelity National Information Services
FIS
$19.5B
– –
-75,000
Closed -$9.96M
NIO icon
103
NIO
NIO
$9.17B
– –
-2,000,000
Closed -$4.02M
NKTR icon
104
Nektar Therapeutics
NKTR
$2.3B
– –
-33,333
Closed -$9.67M
NVDA icon
105
NVIDIA
NVDA
$5.13T
– –
-8,000,000
Closed -$34.8M
XBI icon
106
CALL
State Street SPDR S&P Biotech ETF
XBI
$10.4B
– –
-250,000
Closed -$19.1M
TECX
107
Tectonic Therapeutic
TECX
$567M
– –
-1,954
Closed -$331K
XYZ
108
Block Inc
XYZ
$47.1B
– –
-30,000
Closed -$1.86M
GRTS
109
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
– –
-250,000
Closed -$2.16M
MRTX
110
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-200,000
Closed -$15.6M
GBT
111
DELISTED
Global Blood Therapeutics, Inc.
GBT
– –
-350,000
Closed -$17M
DLPH
112
CALL
DELISTED
Delphi Technologies PLC Ordinary Shares
DLPH
– –
-750,000
Closed -$10.1M
ARQL
113
DELISTED
Arqule Inc
ARQL
– –
-850,000
Closed -$6.09M
BOLD
114
DELISTED
Audentes Therapeutics, Inc
BOLD
– –
-350,000
Closed -$9.83M
MDCO
115
DELISTED
Medicines Co
MDCO
– –
-1,400,000
Closed -$70M
1 2 3 4
5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $931M AUM 47.97% 1-Year Est. Return
ACM
Ashe Capital Management Englewood Cliffs, New Jersey $931M AUM 4.95% 1-Year Est. Return
SAM
Sycomore Asset Management Paris, France $932M AUM 51.25% 1-Year Est. Return
NS
Night Squared New York $930M AUM 56.46% 1-Year Est. Return
PA
Planning Alternatives Birmingham, Michigan $933M AUM 28.32% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $933M AUM 56.2% 1-Year Est. Return
CICI
Capital Investment Counsel Inc Raleigh, North Carolina $929M AUM 53.07% 1-Year Est. Return
CAM
Claret Asset Management Montreal, Quebec, Canada $928M AUM 25.4% 1-Year Est. Return

Artal Group's Q4 2019 Portfolio in Review

As of Q4 2019, Artal Group held 115 positions worth $2.59B, up 3.8% from $2.49B the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Artal Group's Q4 2019 filing shows 13 new, 19 increased, 20 reduced and 19 closed positions. Its largest new stake was BioNTech: 2,628,130 shares worth $89M. The largest sale was Medicines Co, an estimated $70M.

By sector, the portfolio is most concentrated in Healthcare at 63% of assets, up from 53% a quarter earlier, followed by Consumer Discretionary and Miscellaneous.

  • Artal Group's largest Q4 2019 buy was BioNTech: 2,628,130 shares worth $89M.
  • Artal Group added most to Alnylam Pharmaceuticals in Q4 2019, an estimated $29.9M increase.
  • Artal Group's biggest Q4 2019 reduction was Avantor, cutting an estimated $19.9M.
  • Artal Group fully exited Medicines Co in Q4 2019, selling an estimated $70M.
  • Artal Group's ten largest holdings make up 60% of its $2.59B portfolio in Q4 2019.
  • Artal Group opened 13 new positions and closed 19 in Q4 2019.
  • Artal Group's portfolio value rose 3.8% quarter-over-quarter to $2.59B.

Based on Artal Group's 13F filing for Q4 2019, filed 13 Feb 2020.